N-(9-ethyl-9H-carbazol-3-yl)formamide | 80776-22-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-(9-ethyl-9H-carbazol-3-yl)formamide
• 英文别名: ethyl-9 formamido-3 carbazole；N-(9-ethylcarbazol-3-yl)formamide
• CAS: 80776-22-3
• 化学式: C₁₅H₁₄N₂O
• mdl: MFCD21461385
• 分子量: 238.289
• InChiKey: TUEXMZXYADDINU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.86
• 重原子数：
  18.0
• 可旋转键数：
  2.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.133
• 拓扑面积：
  34.03
• 氢给体数：
  1.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  N-(9-ethyl-9H-carbazol-3-yl)formamide 在 三光气 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以89%的产率得到9-ethyl-3-isocyanocarbazole
  参考文献：
  名称：

  Synthesis and Characterization of Gold(I) Complexes with 9‐(4‐Isocyanophenyl)carbazole or 9‐Ethyl‐3‐isocyanocarbazole Ligands

  摘要：

  AbstractThe carbazole derivatives 9‐(4‐isocyanophenyl)carbazole, 3,6‐dibromo‐9‐(4‐isocyanophenyl)carbazole, and 9‐ethyl‐3‐isocyanocarbazole were prepared and used to synthesize [AuX(CN‐carbazole)] (X = Cl, C6F5, C6F4‐OEt‐p) gold complexes. The X‐ray structures of [Au(C6F4‐OEt‐p){9‐(4‐isocyanophenyl)carbazole}] and [Au(C6F5)(9‐ethyl‐3‐isocyanocarbazole)], and the luminescent properties of the ligands and the complexes in the solid state, in solution at room temperature, and in frozen solution of chloroform at 77 K were determined. All the gold complexes show a redshift in the emissions relative to that of the free ligand. The presence of electron‐withdrawing substituents in 3,6‐dibromo‐9‐(4‐isocyanophenyl)carbazole quenches the luminescence, but with the introduction of a gold atom some luminescence is recovered.(© Wiley‐VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009)

  DOI：

  10.1002/ejic.200900692
• 作为产物：
  描述：

  甲酸 、 3-氨基-9-乙基咔唑 反应 2.5h， 以84%的产率得到N-(9-ethyl-9H-carbazol-3-yl)formamide
  参考文献：
  名称：

  Lancelot, Jean-Charles; Gazengel, Jean-Marie; Robba, Max, Journal of Heterocyclic Chemistry, 1981, vol. 18, p. 1281 - 1285

  摘要：

  DOI：

文献信息

• Transamidation of Carboxamides Catalyzed by Fe(III) and Water
  作者：Liliana Becerra-Figueroa、Andrea Ojeda-Porras、Diego Gamba-Sánchez

  DOI：10.1021/jo500562w

  日期：2014.5.16

  The highly efficient transamidation of several primary, secondary, and tertiary amides with aliphatic and aromatic amines (primary and secondary) is described. The reaction is performed in the presence of a 5 mol % concentration of different hydrated salts of Fe(III), and the results show that the presence of water is crucial. The methodology was also applied to urea and phthalimide to demonstrate

  描述了几种伯，仲和叔酰胺与脂族和芳族胺（伯和仲）的高效氨基转移。反应在浓度为5 mol％的不同水合Fe（III）盐存在下进行，结果表明水的存在至关重要。该方法还应用于尿素和邻苯二甲酰亚胺，以证明其多功能性和广泛的底物范围。其用途的一个实例是分子内应用，用于合成2,3-二氢-5 H-苯并[ b ] -1,4-噻嗪平-4-酮，它是地尔硫卓与结构相关药物的双环核心（Budriesi ，R。; Cosimelli，B。;伊万，P。; Carosati，E。; Ugenti，MP; Spisani，R. CURR医学化学式。2007年，14，279–287）。在实验观察和先前关于由过渡金属（例如铜和铝）催化的氨基转移反应的机理建议的基础上，提出了一种解释水作用的合理机制。与其他现有方法相比，该方法具有显着改进。它可以在空气中和湿或工业级溶剂中进行。
• Synthesis of 2-Aminopyridines via a Base-Promoted Cascade Reaction of <i>N</i>-Propargylic β-Enaminones with Formamides
  作者：Yunxiang Weng、Changsheng Kuai、Weiwei Lv、Guolin Cheng

  DOI：10.1021/acs.joc.8b00128

  日期：2018.5.4

  N-Substituted formamides as nucleophiles react with in situ-generated 1,4-oxazepines from N-propargylic β-enaminones followed by spontaneous N-deformylation to deliver densely substituted 2-aminopyridines in good yields (31–88%). The formyl group is found to be a superior traceless activating group of free amines and would ultimately be removed in situ. This reaction proceeds smoothly at room temperature

  N-取代的甲酰胺作为亲核试剂与N-炔丙基β-烯胺酮原位生成的1,4-氧杂氮杂苯反应，然后自发地进行N-甲酰化，从而以高收率（31-88％）提供密集取代的2-氨基吡啶。发现甲酰基是游离胺的优良的无痕活化基团，最终将被原位除去。该反应在室温下在作为唯一添加剂的NaOH的存在下平稳进行，没有受到大气的保护，并生成H 2 O和甲酸钠作为副产物。
• NPY Y5 ANTAGONIST
  申请人：KAWANISHI Yasuyuki

  公开号：US20100292500A1

  公开（公告）日：2010-11-18

  The present invention provides a pharmaceutical composition for use as art NPY Y5 receptor antagonist comprising a compound or the formula (I): wherein R 1 is lower alkyl, cycloalkyl or the like, R 2 is hydrogen, lower alkyl or the like, n is 1 or 2, X is lower alkylene, lower alkenylene, arylene, cycloalkylene or the like, Y is CONR 7 , CSNR 7 , NR 7 CO, NR 7 CS or the like, Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like and R 7 is hydrogen or lower alkyl, prodrug, pharmaceutically acceptable salt or solvate thereof.

  本发明提供了一种药物组合物，用作NPY Y5受体拮抗剂，包括化合物或式（I）：其中R1为低碳基、环烷基或类似物，R2为氢、低碳基或类似物，n为1或2，X为低碳基、低烯基、芳基、环烷基或类似物，Y为CONR7、CSNR7、NR7CO、NR7CS或类似物，Z为低碳基、可选取代的碳环基、可选取代的杂环基或类似物，R7为氢或低碳基，前药、药学上可接受的盐或溶剂。
• NPYY5 antagonists
  申请人：Shionogi&Co., Ltd.

  公开号：EP2014285A1

  公开（公告）日：2009-01-14

  The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound of the formula (I): wherein R1 is lower alkyl, cycloalkyl or the like, R2 is hydrogen, lower alkyl or the like, n is 1 or 2, X is lower alkylene, lower alkenylene, arylene, cycloalkylene or the like, Y is CONR7, CSNR7, NR7CO, NR7CS or the like, Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like and R7 is hydrogen or lower alkyl, prodrug, pharmaceutically acceptable salt or solvate thereof

  本发明提供了一种用作 NPY Y5 受体拮抗剂的药物组合物，该组合物由式（I）化合物组成： 其中 R1 是低级烷基、环烷基或类似物、 R2 是氢、低级烷基或类似物、 n 是 1 或 2、 X 是低级烯烃、低级烯烃、芳基、环烷烃或类似物、 Y 是 CONR7、CSNR7、NR7CO、NR7CS 或类似物、 Z 是低级烷基、任选取代的碳环烷基、任选取代的杂环烷基或类似物，R7 是氢或低级烷基、 其原药、药学上可接受的盐或溶液
• LANCELOT, J. -C.;GAZENGEL, J. -M.;ROBBA, M., J. HETEROCYCL. CHEM., 1981, 18, N 7, 1281-1285
  作者：LANCELOT, J. -C.、GAZENGEL, J. -M.、ROBBA, M.

  DOI：——

  日期：——